Piperacetazine - Misplaced Pages

Chemical compound

Pharmaceutical compound

Piperacetazine
Clinical data

Trade names	Actazine, Quide, Psymod
AHFS/Drugs.com	International Drug Names
Identifiers
IUPAC name 1-propyl]phenothiazin-2-yl]ethanone
CAS Number	3819-00-9
PubChem CID	19675
ChemSpider	18533
UNII	KL6248WNW4
ChEBI	CHEBI:92293
ChEMBL	ChEMBL1584
CompTox Dashboard (EPA)	DTXSID7023481
ECHA InfoCard	100.021.194
Chemical and physical data
Formula	C₂₄H₃₀N₂O₂S
Molar mass	410.58 g·mol
3D model (JSmol)	Interactive image
SMILES CC(=O)c1ccc2Sc3ccccc3N(CCCN4CCC(CCO)CC4)c2c1
InChI InChI=InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3 Key:BTFMCMVEUCGQDX-UHFFFAOYSA-N

Piperacetazine (Quide) is an antipsychotic prodrug, most notably used for schizophrenia. It is a phenothiazine derivative. Based on clinical trial data, it appears to have similar efficacy as chlorpromazine. However, very little research has been done since the 1970s, and it is not a commonly used drug today.

Side effects

The side effect profile of piperacetazine is similar to that of other typical antipsychotics. The most common side effects of piperacetazine are dizziness, drowsiness, fainting, orthostatic hypotension, and extrapyramidal symptoms. Less common side effects include nausea, vomiting, bradycardia, euphoria, and headache. Rare side effects include leukopenia, thrombocytopenia, galactorrhea, amenorrhea, seizures, urinary retention, and jaundice.

References

Rada RT, Donlon PT (February 1974). "Piperacetazine in ambulatory chronic schizophrenic patients". Current Therapeutic Research, Clinical and Experimental. 16 (2): 124–129. PMID 4156665.
^ Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R (October 2018). "Chlorpromazine versus piperacetazine for schizophrenia". The Cochrane Database of Systematic Reviews. 10 (10): CD011709. doi:10.1002/14651858.CD011709.pub2. PMC 6517193. PMID 30378678.

v t e Antipsychotics (N05A)
Typical	Butyrophenones: Benperidol Bromperidol Bromperidol decanoate Droperidol Haloperidol Haloperidol decanoate Moperone Pipamperone Spiperone Timiperone Trifluperidol Diphenylbutylpiperidines: Fluspirilene Penfluridol Pimozide Phenothiazines: Acepromazine Acetophenazine Butaperazine Carphenazine (carfenazine) Chlorpromazine Cyamemazine Dixyrazine Fluphenazine Fluphenazine decanoate Fluphenazine enanthate Levomepromazine (methotrimeprazine) Mesoridazine Perazine Periciazine Perphenazine BL-1020 Perphenazine decanoate Perphenazine enanthate Piperacetazine Pipotiazine Pipotiazine palmitate Pipotiazine undecylenate Prochlorperazine Promazine Sulforidazine Thiopropazate Thioproperazine Thioridazine Trifluoperazine Triflupromazine Thioxanthenes: Chlorprothixene Clopenthixol Clopenthixol decanoate Flupentixol Flupentixol decanoate Tiotixene (thiothixene) Zuclopenthixol Zuclopenthixol acetate Zuclopenthixol decanoate
Disputed	Benzamides: Amisulpride Levosulpiride Nemonapride Remoxipride Sulpiride Sultopride Tiapride Veralipride Butyrophenones: Melperone Tricyclics: Carpipramine Clocapramine Clorotepine Clotiapine Loxapine Mosapramine Oxyprothepin decanoate Others: Molindone
Atypical	Benzisoxazole/benzisothiazoles: Iloperidone Lurasidone Paliperidone Paliperidone palmitate Perospirone Risperidone Ziprasidone Butyrophenones: Lumateperone Phenylpiperazines/quinolinones: Aripiprazole Aripiprazole lauroxil Brilaroxazine Brexpiprazole Cariprazine Tricyclics: Asenapine Clozapine Olanzapine (+samidorphan) Quetiapine Zotepine Others: Blonanserin Pimavanserin Sertindole
Others	Monoamine-depleting agents: Oxypertine Reserpine Tetrabenazine Muscarinic agonists: Xanomeline/trospium chloride Others/unknown: Azacyclonol
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: